Video Chart analysis and commentary on Trius Therapeutics (TSRX).
From the Aegis analyst report, we read the following:
In the wake of this data, we are raising our probability of success
for tedizolid from 60% to 80%, which increases the risk-adjusted Net Present
Value (rNPV) from $650mm to $840mm. We anticipate that Trius could
submit a New Drug Application (NDA) filing on tedizolid to the FDA by midto
late 2013. As such, the drug could be approved in the U.S. in 2014. We also
expect the full data set from the ESTABLISH-2 study to be presented at the
ICAAC Conference in Denver, CO in September 2013. Given this positive
data, we reiterate our Buy rating and raise our 15-month price target from
$14.00 to $18.00 per share.
My very short term target is $8.12, with the next target after that over $9, then I believe by mid-summer, we will be approaching $12, if the company does not see a tender offer from Cubist Pharmaceuticals (CBST) or another big player before then. DD and articles to refer to on TSRX below: